HPPI Insider Trading Activity and SEC Form 4 Filings
HPPI insider trading summary
No open-market insider purchases or sales of HedgePath Pharmaceuticals, Inc. (HPPI) have been reported on SEC Form 4 in the past 12 months.
Latest HPPI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 30, 2018 | Garrison J. Hasara | CFO and Treasurer | Sell | $27K (100,000 @ $0.27) |
| Dec 19, 2017 | Mayne Pharma Ventures Pty Ltd | 10% Owner | Buy | $97.60B (600,000 @ $162660.00) |
| Dec 19, 2017 | Stefan Cross | Director | Buy | $97.60B (600,000 @ $162660.00) |
| Dec 19, 2017 | Mayne Pharma International Pty Ltd | 10% Owner | Buy | $97.60B (600,000 @ $162660.00) |
| Dec 19, 2017 | Mayne Pharma Group Ltd | 10% Owner | Buy | $97.60B (600,000 @ $162660.00) |
| Jun 30, 2017 | HedgePath, LLC | 10% Owner | Sell | $0 (2,500,000 @ $0.00) |
| Jun 15, 2016 | Francis E Odonnell Jr | Executive Chairman | Sell | $0 (2,560,000 @ $0.00) |
| Jun 15, 2016 | HedgePath, LLC | 10% Owner | Sell | $0 (2,560,000 @ $0.00) |
| Sep 10, 2015 | Francis E Odonnell Jr | Executive Chairman | Buy | $0 (20,000,000 @ $0.00) |
| Sep 10, 2015 | HedgePath, LLC | 10% Owner | Sell | $0 (20,000,000 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.